Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatoryVariousPharmaceuticalsSafety Signal

Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity

The Class 3 recall by Bayer Plc due to an impurity poses significant risks to their market share and consumer trust. This situation necessitates a thorough investigation into the implications for Bayer's product portfolio and potential regulatory responses.

Published: June 27, 2026
Updated: June 27, 2026
Author: Humanexa Intelligence
Therapeutic area: Various / Pharmaceuticals
Company: Bayer
Asset: Various Products
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Bayer

Asset

Various Products

Indication

Various / Pharmaceuticals

Status

Under Review

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The Class 3 recall by Bayer Plc due to an impurity poses significant risks to their market share and consumer trust. This situation necessitates a thorough investigation into the implications for Bayer's product portfolio and potential regulatory responses.

Why it matters

The Class 3 recall by Bayer Plc due to an impurity poses significant risks to their market share and consumer trust. This situation necessitates a thorough investigation into the implications for Bayer's product portfolio and potential regulatory responses.

What changed

Safety Signal

Analysis

Bayer Plc is recalling all stock of certain products due to an impurity identified above acceptable limits.

The Class 3 recall by Bayer Plc due to an impurity poses significant risks to their market share and consumer trust. This situation necessitates a thorough investigation into the implications for Bayer's product portfolio and potential regulatory responses.

Monitor for updates on the recall process and any regulatory actions that may follow.

Related companies & assets

Companies

  • Bayer →
  • various pharmaceutical products →

Assets

  • Various Products →

Sources & Humanexa intelligence

Source links

  • Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity ↗

Related Humanexa pages

  • Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Biogen

Asset

FDA

Indication

Neurology / Depression

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Accepts Supplemental NDA for Zuranolone (ZURZUVAE) by Biogen

The FDA has accepted a supplemental NDA for Zuranolone (ZURZUVAE) submitted by Biogen.

July 5, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Aurobindo Pharma

Asset

Canagliflozin

Indication

Diabetes / SGLT2 Inhibitor

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

Aurobindo Pharma's ANDA for Canagliflozin Receives Approval Status

Aurobindo Pharma's ANDA210386 for Canagliflozin has received an approval status (AP) from the FDA.

July 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.